Expert Perspectives on the Role of BTK Inhibitors in B-Cell Malignancies: What Managed Care Needs to Know for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management
of B-Cell malignancies with BTK inhibitors, including how to translate the
most recent data into clinical and administrative practice.

These are archives of live webinars held between April 1 to April 22, 2020.
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

Each session has its own specific valid dates

This series is supported by educational grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company
and Janssen Biotech, Inc.

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Bruton's tyrosine kinase (BTK) is an enzyme that in humans is encoded by the BTK gene. BTK is abundantly expressed and constitutively active in the pathogenesis of B cell hematological malignancies. Therefore, BTK is considered as an attractive target for treatment of B-cell malignancies. These options, known as BTK inhibitors, have changed the treatment paradigm in several different B-cell malignancies in recent years. These agents differ in dosing, efficacy, and toxicities, and as these options for B-cell malignancies grow, it is essential to understand their clinical and economic role in the treatment paradigm to offer patients the safest and most efficacious treatment, while also controlling costs.

A Deeper Look into BTK Inhibitors in the Management of B-Cell Malignancies: Individualizing Treatment for Improved Clinical and Economic Outcomes

1. Compare and contrast the BTK inhibitors, including their pharmacological differences
2. Discuss key published clinical trials, ongoing clinical trials, and guideline recommendations for BTK inhibitors in B-Cell malignancies, with a focus on chronic lymphocytic leukemia (CLL)
3. Formulate effective strategies for ensuring the proper selection and use of BTK inhibitors in the care of individual patients and patient populations
4. Identify patients with B-Cell malignancies, with a focus on CLL, for whom a BTK inhibitor is an appropriate choice for the next step in the management of their cancer

Improving Patient Adherence and Quality of Life in Managing B-Cell Malignancies with BTK Inhibitors: Strategies for Anticipating, Recognizing, and Managing Adverse Events

1. Compare BTK inhibitors in B-Cell malignancies, with a focus on CLL, including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use
2. Discuss strategies to mitigate and manage predictable toxicities that have been reported with the use of BTK inhibitors in B-Cell malignancies, with a focus on CLL
3. Discuss methods to communicate effectively with cancer patients and the multidisciplinary team to understand and address the needs of each patient around BTK inhibitors and improve treatment adherence, quality of life, and survival outcomes
4. Review how treatment strategies can be affected by adverse events based on patient’s individualized needs

Comparative Effectiveness and Coordinated Care of BTK Inhibitors: What Does Managed Care Need to Know?

1. Evaluate managed care considerations on optimizing the use of BTK inhibitors in B-Cell malignancies, with a focus on CLL, managing therapy-related toxicities, improving adherence, expanding payer/provider communication, and aiding in the implementation of clinical pathways to deliver quality care
2. Transform therapeutic advances and resource utilization data on BTK inhibitors into informed health plan decisions
3. Apply methods to enable optimal cost management of BTK inhibitors to be realized by multiple stakeholders, including managed care organizations
4. Examine key economic challenges surrounding the use of BTK inhibitors in B-Cell malignancies